A drug developer wants to shake up the clinical trial process through crowdsourcing as well as using telemedicine and greater data transparency. It believes implementing these together can cut the cost of doing clinical trials by 50 percent in the next two years.
Transparency Life Sciences is a New York-based startup that was founded by CEO Tomasz Sablinski, also currently the head of development at Celtic Therapeutics , and Marc Foster, Transparency’s chief operating officer, who previously worked at FoldRx Pharmaceuticals before it was acquired by Pfizer (NYSE:PFE). The company plans to develop refocused compounds before embarking on novel drugs. Foster spoke about the company’s plans in a phone interview with MedCity News.
To read the full, original article click on this link: 4 ways to shake up the clinical trial process and cut costs
